Citation:Tian LL,Ren B,Gao XW,Luo Y,Cai Y,Zhou K,Du AJ,Zhao Y.Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib.Int J Ophthalmol 2014;7(2):198-204,doi:10.3980/j.issn.2222-3959.2014.02.03
Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib
Received:October 31, 2013  Revised:December 11, 2013
Email this Article  Add to Favorites  Print
DOI:10.3980/j.issn.2222-3959.2014.02.03
Key Words:sorafenib; retinopathy of prematurity; neovascularization; tyrosine kinase inhibitors
Fund Project:
Conflicts of Interest: Tian LL, None; Ren B, None; Gao XW, None; Luo Y, None; Cai Y, None; Zhou K, None; Du AJ, None; ZhaoY, None.
                       
AuthorInstitution
Li-Li Tian Medical College of Shihezi University, Shihezi , Xinjiang Uygur Autonomous Region, China
;Ophthalmic Center, No.474 Hospital of Chinese PLA, Urumqi , Xinjiang Uygur Autonomous Region, China
Bing Ren Ophthalmic Center, No.474 Hospital of Chinese PLA, Urumqi , Xinjiang Uygur Autonomous Region, China
Xiao-Wei Gao Ophthalmic Center, No.474 Hospital of Chinese PLA, Urumqi , Xinjiang Uygur Autonomous Region, China
Ying Luo Ophthalmic Center, No.474 Hospital of Chinese PLA, Urumqi , Xinjiang Uygur Autonomous Region, China
Yan Cai Ophthalmic Center, No.474 Hospital of Chinese PLA, Urumqi , Xinjiang Uygur Autonomous Region, China
Kun Zhou Medical College of Shihezi University, Shihezi , Xinjiang Uygur Autonomous Region, China
;Ophthalmic Center, No.474 Hospital of Chinese PLA, Urumqi , Xinjiang Uygur Autonomous Region, China
An-Jie Du Department of Ophthalmology, Yuncheng Central Hospital, Yuncheng , Shanxi Province, China
Yong Zhao Ophthalmic Center, No.474 Hospital of Chinese PLA, Urumqi , Xinjiang Uygur Autonomous Region, China
Hits: 949
Download times: 219
Abstract:
      AIM:To investigate the effect of intravitreal injection administered sorafenib, a multikinase inhibitor, in a rat model of oxygen-induced retinopathy (OIR).

    METHODS:Seven-day-old Sprague-Dawley rats (n=144) were randomly assigned to six groups. Group A received normal partial oxygen pressure and groups B, C, D, E and F were exposed to hyperoxia (75±2)% from postnatal 7d (P7) to P12 to induce retinopathy of prematurity. The rats in groups C, D, E and F were received intravitreal injections of either vehicle (DMSO) or sorafenib at P12 (5, 20 and 80 μg, respectively). Then they returned to normoxia after P12. The retinas were whole-mounted and imaged with a confocal microscopy. The vascular branching points were counted to quantify neovascularization at P17. Cross-sections of the retina were stained with hematoxylin and eosin (HE). The nuclei of new vessels breaking the internal limiting membrane were counted to quantify the proliferative neovascular response.

    RESULTS:The retinal vessel in groups B and C turned into tortuosity and a great deal of neovascularization were observed. Sorafenib-treated rats had significantly less neovascularization as compared with vehicle-treated and control rats in a dose dependent manner (P<0.05). The number of vascular branching points in A, B, C, D, E and F were 16.50±3.90, 37.44±6.47, 37.08±5.10, 30.80±6.85, 26.08±5.08 and 19.83±3.51, respectively. The number of the nuclei of retinal new vessel in A, B, C, D, E and F were 0.22±0.42, 35.66±4.70, 35.30±4.54, 27.30±4.28, 21.41±3.53, and 7.41±2.87, respectively. There were significant difference between each group (P<0.05) except groups B and C.

    CONCLUSION: In the rat OIR model, sorafenib could inhibit retinal neovascularization in a dose dependent manner.

PMC FullText Html:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003070/
PDF Fulltext  Download reader  HTML Fulltext   View/Add Comment